PRISM BioLab Co.,LTD (TYO:206A)
Japan · Delayed Price · Currency is JPY 186.00
-6.00 (-3.13%)
At close: Feb 6, 2026
PRISM BioLab Co.,LTD Company Description
PRISM BioLab Co.,LTD engages in the research and development of pharmaceuticals using its proprietary drug discovery platform technology, PepMetics Technology.
It develops E7386 targeting CBP/beta-catenin, which is in Phase II clinical trial for the treatment of cancer; and PRI724 targeting CBP/beta-catenin that is in Phase II clinical trial for treating cirrhosis.
The company was founded in 2006 and is based in Fujisawa, treating Japan.
PRISM BioLab Co.,LTD
| Country | Japan |
| Founded | 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 35 |
| CEO | Dai Takehara |
Contact Details
Address: 2-26-1, Muraoka-Higashi Fujisawa, 251-8555 Japan | |
| Phone | 81 4 6653 8383 |
| Website | prismbiolab.com |
Stock Details
| Ticker Symbol | 206A |
| Exchange | Tokyo Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | October - September |
| Reporting Currency | JPY |
| ISIN Number | JP3833190006 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dai Takehara | Chief Executive Officer |